Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial

Response to Comment On: Perry et al. (2009) Interrogating Type 2 Diabetes Genome-Wide Association Data Using a Biological Pathway-Based Approach. Diabetes;58:1463-1467

(2009) J. R.B. Perry et al.   DIABETES

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity

(2008) S. R. Smith et al.   DIABETES CARE

Antiobesity effects of the β-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats

(2008) J D Roth et al.   INTERNATIONAL JOURNAL OF OBESITY

Adjustable Gastric Banding and Conventional Therapy for Type 2 Diabetes

(2008) John B. Dixon et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A critical review of the cannabinoid receptor as a drug target for obesity management

(2008) F. Akbas et al.   Obesity Reviews

Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies

(2008) J. D. Roth et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA